Cerevel (CERE) - EV/EBITDA Multiple
Cerevel Therapeutics (CERE), developing with the support of AbbVie, is creating advanced therapies for Parkinson's disease and schizophrenia. The company leverages robotic laboratories and AI to design compounds targeting CNS pathologies. The price action on the GURU.Markets platform chart shows that the separate_ev_ebitda metric stands at . However, financial stability is constrained by high costs and the probability of regulatory drug rejections.
cerevel.com (CERE) - metric breakdowns and financial figures
- market price and analyst price targets:
- market capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Debt to Equity Cerevel Therapeutics|CERE - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Cerevel Therapeutics, Inc.|CERE - Aggregate Debt Obligations|Debt to Book Value Cerevel Corp|CERE - Amount of Long-Term Liabilities|Company Short-Term Debts Cerevel Therapeutics|Quick Ratio cerevel.com
- net income and valuation multiples indicators:
CERE - Company Net Income|Expected Profit Cerevel Therapeutics|CERE - Company Value to Net Income|Forward P/E Multiple Cerevel Therapeutics|CERE - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cerevel Corp|CERE - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Cerevel Therapeutics|CERE - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months cerevel.com|CERE - Earnings growth in current year|Expected earnings per share growth for next year Cerevel Therapeutics
- sales revenue and business income indicators:
Summary company analysis:Cerevel (CERE)
Investors face a choice between the asset's current overvaluation and its growth potential amid high risks. This EV/EBITDA multiple compares total market capitalization plus debt against operating profit before taxes, allowing for an assessment of the business's real value. For Cerevel Therapeutics (CERE), this indicator is critical in the context of the acquisition by AbbVie and the success of emraclidine and tavapadone.
Competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Business Value to Operating Income Before Depreciation NBIX|Regencell Bioscience - EV/EBITDA Multiple|Company Value to EBITDA axsome.com|ACAD (ACADIA Pharmaceuticals Inc.) - Enterprise Value to EBITDA Ratio|XENE (Xenon Pharmaceuticals Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VKTX (Viking Pharma) - EV/EBITDA Multiple|Company Value to EBITDA Supernus Corp SUPN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharmaceuticals (CPRX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DNLI (denalitherapeutics.com)|Harmony Biosciences Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHVN|AMLX: Enterprise Value to EBITDA Ratio|Trevi Corp - Enterprise Value to Operating Income Before Depreciation Ratio|PRAX: EV/EBITDA Multiple|anavex.com - Business Value to Operating Income Before Depreciation|CBLL (CeriBell) - EV/EBITDA Multiple|Company Value to EBITDA Prothena Corporation PLC PRTA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|ANNX (Annexon Biosciences Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple OMER (Omeros)|EV/EBITDA Multiple neurogene.com NGNE|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VYGR|NMRA: EV/EBITDA Multiple|Company Value to EBITDA Scilex Holding Company, Inc. (SCLX)|Enterprise Value to EBITDA Ratio TVGN|EV/EBITDA Multiple Alpha Cognition Corp|Enterprise Value to EBITDA Ratio CGTX (Cognition Therapeutics, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio IKT|EV/EBITDA Multiple SAVA (Cassava)|Total Company Value to Operating Income Before Depreciation Ratio Assertio Holdings (ASRT)|Coya - EV/EBITDA Multiple|Vistagen Therapeutics (VTGN) - Enterprise Value to EBITDA Ratio|ovidrx.com (OVID) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ABOS - Total Company Value to Operating Income Before Depreciation Ratio|CRVO (CervoMed Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Alterity Therapeutics Ltd (ATHE)|EV/EBITDA Multiple CLNN|PEPG - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|Business Value to Operating Income Before Depreciation RLMD|Annovis Bio Corp - EV/EBITDA Multiple|Company Value to EBITDA Grace Therapeutics, Inc.|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation KLTO|NRSN (NeuroSense Therapeutics Ltd) - EV/EBITDA Multiple|Company Value to EBITDA Reviva Pharmaceuticals Holdings Inc. RVPH|Enterprise Value to EBITDA Ratio MTVA (MetaVia Inc)|EV/EBITDA Multiple NeurAxis Inc (NRXS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Helius Medical Technologies HSDT|Business Value to Operating Income Before Depreciation PASG|NEUP - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Minerva Neurosciences Inc|ATHA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Addex|ALZN (Alzamend Neuro Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Cyclerion CYCN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protagenic Therapeutics (PTIX)|KTTA (pasitheaclinics.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CRGT (Cortigent)|Avenue Therapeutics Inc (ATXI) - Company Value to EBITDA|BCLI: Enterprise Value to EBITDA Ratio|CARA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CHRO: EV/EBITDA Multiple|Company Value to EBITDA Eliem Therapeutics Inc. (ELYM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intra-Cellular Therapies Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LBPH|Enterprise Value to EBITDA Ratio MRNS (Marinus Pharmaceuticals)|NKGN (nkgenbiotech.com) - Business Value to Operating Income Before Depreciation|NeuroBo Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SAGE (Sage Therapeutics Inc.)|Neurotrope - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation TRVN (Trevena Inc)|VIGL: EV/EBITDA Multiple|Company Value to EBITDA anewmeds.com (WENA)
